Creative Medical Technology Holdings (CELZ) Shares Outstanding (2010 - 2026)
Creative Medical Technology Holdings (CELZ) posted quarterly Shares Outstanding (Entity) of $6.1 million for Q1 2026, up 47.09% year-over-year from $4.1 million in Q1 2025, and little changed quarter-over-quarter from $6.1 million in Q4 2025.
Creative Medical Technology Holdings (CELZ) Shares Outstanding (2010 - 2026) Analysis & Trends
Creative Medical Technology Holdings (CELZ) has reported Shares Outstanding (Entity) for 17 consecutive years, with $6.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Shares Outstanding (Entity) rose 47.09% year-over-year to $6.1 million; the TTM figure through Mar 2026 stood at $6.1 million (up 47.09% YoY), while the FY2025 annual figure was $6.1 million, up 91.56% from the prior year.
- Shares Outstanding (Entity) held at $6.1 million in Q1 2026 per CELZ's latest filing, from $6.1 million in the prior quarter.
- Across five years, Shares Outstanding (Entity) topped out at $6.1 million in Q4 2025 and bottomed at $652069.0 in Q1 2022.
- Historically, Shares Outstanding (Entity) has averaged $2.2 million across 5 years, with a median of $1.4 million in 2023.
- Annual changes were most pronounced in 2022 — Shares Outstanding (Entity) surged 472.61% — and 2024, when it dropped 0.0%.
- Creative Medical Technology Holdings' Shares Outstanding (Entity) stood at $1.1 million in 2022, then soared by 30.91% to $1.4 million in 2023, then surged by 122.54% to $3.2 million in 2024, then soared by 91.56% to $6.1 million in 2025, then changed by 0.0% to $6.1 million in 2026.
- Business Quant data shows CELZ's Shares Outstanding (Entity) at $6.1 million in Q1 2026, $6.1 million in Q4 2025, and $4.1 million in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 62.19 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 398.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 111.58 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 133.61 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 217.35 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 445.06 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 241.70 Mn |
| 10 | Creative Medical Technology Holdings | 1.83 Mn | 1.83 Mn | - | 1.43 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 8.89 Mn |
| Mar 31, 2026 | 6.10 Mn |
| Dec 31, 2025 | 6.10 Mn |
| Sep 30, 2025 | 4.15 Mn |
| Jun 30, 2025 | 4.15 Mn |
| Mar 31, 2025 | 4.15 Mn |
| Dec 31, 2024 | 3.18 Mn |
| Sep 30, 2024 | 1.39 Mn |
| Jun 30, 2024 | 1.41 Mn |
| Mar 31, 2024 | 1.42 Mn |
| Dec 31, 2023 | 1.41 Mn |
| Sep 30, 2023 | 1.43 Mn |
| Jun 30, 2023 | 1.41 Mn |
| Mar 31, 2023 | 1.41 Mn |
| Dec 31, 2022 | 1.09 Mn |
| Sep 30, 2022 | 1.41 Mn |
| Jun 30, 2022 | 901,125.00 |
| Mar 31, 2022 | 645,402.00 |
| Dec 31, 2021 | 324,862.00 |
| Sep 30, 2021 | 245,208.00 |